AstraZeneca (LON:AZN) Given Hold Rating at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft restated their hold rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Tuesday morning, Marketbeat.com reports. They currently have a £105 ($129.69) target price on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the company. Barclays restated an overweight rating and issued a £125 ($154.40) price target on shares of AstraZeneca in a report on Monday, April 8th. BMO Capital Markets restated an outperform rating on shares of AstraZeneca in a report on Monday, February 12th. Berenberg Bank restated a buy rating on shares of AstraZeneca in a report on Wednesday, March 13th. JPMorgan Chase & Co. restated an overweight rating on shares of AstraZeneca in a report on Thursday, April 4th. Finally, Shore Capital reaffirmed a buy rating on shares of AstraZeneca in a research report on Monday, April 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus target price of £116.86 ($144.34).

AstraZeneca Stock Performance

Shares of AstraZeneca stock opened at £113.72 ($140.46) on Tuesday. The firm has a market cap of £176.27 billion, a price-to-earnings ratio of 3,718.81, a price-to-earnings-growth ratio of 0.89 and a beta of 0.19. The stock’s 50-day moving average is £104.63 and its 200-day moving average is £104.27. AstraZeneca has a one year low of GBX 9,461 ($116.86) and a one year high of £123.48 ($152.52). The company has a debt-to-equity ratio of 75.70, a current ratio of 0.82 and a quick ratio of 0.59.

AstraZeneca Increases Dividend

The firm also recently declared a dividend, which was paid on Monday, March 25th. Shareholders of record on Thursday, February 22nd were given a dividend of GBX 156 ($1.93) per share. This represents a yield of 1.49%. The ex-dividend date of this dividend was Thursday, February 22nd. This is an increase from AstraZeneca’s previous dividend of $71.80. AstraZeneca’s payout ratio is 7,524.75%.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.